Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Current Medicinal Chemistry
|
July 7, 2011
Nonprofit pharma: solutions to what ails the industry
W H Moos, K Kodukula
Journal of Medicinal Chemistry
|
July 1, 1986
Drug development for senile cognitive decline
F M Hershenson, W H Moos
Current Opinion in Biotechnology
|
December 1, 1993
Pharmaceutical applications of biotechnology: promise and reality
W H Moos, V J DiRita, D L Oxender
Psychopharmacology
|
January 1, 1989
Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide
L T Meltzer, K A Serpa, W H Moos
Journal of Medicinal Chemistry
|
October 1, 1985
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists
W H Moos, D S Szotek, R F Bruns
Medicinal Research Reviews
|
July 1, 1988
Cognition activators
W H Moos, R E Davis, R D Schwarz, et al.
Bioorganic & Medicinal Chemistry
|
October 26, 1999
Combinatorial discovery process yields antimicrobial peptoids
S Ng, B Goodson, A Ehrhardt, et al.
Journal of Medicinal Chemistry
|
November 1, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity
I Sircar, R E Weishaar, D Kobylarz, et al.
Critical Reviews in Neurobiology
|
January 1, 1993
Therapeutic intervention in dementia
R E Davis, M R Emmerling, J C Jaen, et al.
Journal of Medicinal Chemistry
|
September 1, 1984
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure
J A Bristol, I Sircar, W H Moos, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Current Medicinal Chemistry
|
July 7, 2011
Nonprofit pharma: solutions to what ails the industry
W H Moos, K Kodukula
Journal of Medicinal Chemistry
|
July 1, 1986
Drug development for senile cognitive decline
F M Hershenson, W H Moos
Current Opinion in Biotechnology
|
December 1, 1993
Pharmaceutical applications of biotechnology: promise and reality
W H Moos, V J DiRita, D L Oxender
Psychopharmacology
|
January 1, 1989
Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide
L T Meltzer, K A Serpa, W H Moos
Journal of Medicinal Chemistry
|
October 1, 1985
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists
W H Moos, D S Szotek, R F Bruns
Medicinal Research Reviews
|
July 1, 1988
Cognition activators
W H Moos, R E Davis, R D Schwarz, et al.
Bioorganic & Medicinal Chemistry
|
October 26, 1999
Combinatorial discovery process yields antimicrobial peptoids
S Ng, B Goodson, A Ehrhardt, et al.
Journal of Medicinal Chemistry
|
November 1, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity
I Sircar, R E Weishaar, D Kobylarz, et al.
Critical Reviews in Neurobiology
|
January 1, 1993
Therapeutic intervention in dementia
R E Davis, M R Emmerling, J C Jaen, et al.
Journal of Medicinal Chemistry
|
September 1, 1984
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure
J A Bristol, I Sircar, W H Moos, et al.
Page
of 3